Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
MODERNISED is our two-year, NIHR (National Institute for Health and Care Research) / Office for Life Sciences-funded (Department of Health and Social Care and Department for Science, Innovation and Technology) clinical study led by the Southampton Clinical Trials Unit and Proteotype Diagnostics. The trial will enrol 1,350 volunteers across southern-England NHS hospitals to validate Enlighten®. MODERNISED aims to lay the groundwork for a scalable multi-cancer screening programme in the NHS
Enlighten® is a first-in-class Multi-Cancer Early Detection test that measures the host response to tumour development, strongest in early-stage cancers, using an affordable, fluorescence-kit-based microplate reader assay.
Our biorthogonal chemistry enables direct measurement of the host response from crude patient plasma, eliminating complex sample preparation. Enlighten® is built for real-word adoption.
Our unique technology allows whole blood samples to remain at room temperature in
common and inexpensive standard EDTA collection tubes for up to 48 hours before processing into plasma. This enables accessible sample collection in distributed settings (pharmacies and mobile vans).
MODERNISED is evaluating Enlighten® in Breast, Colorectal, Prostate, Pancreatic, Lung, Melanoma, Oesophageal, Ovarian, Bladder, and Renal cancer.
MODERNISED: A prospective observational study to generate evidence on the performance characteristics of Enlighten®, and to design a NHS programme for the use of the test, providing acceptable, effective, equitable, and cost-effective screening.
Copyright © 2025 Proteotype Diagnostics - All Rights Reserved.
Patent Pending in 19 Jurisdictions
Disclaimer: For Performance Evaluation Only - Not For Diagnostic Use.